Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-09-09 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a generic pharmaceutical product in the United States following FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is 4277 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, no voting results, no management changes, or other regulatory filings. Therefore, this document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-09-09 English
Lupin Launches Generic Suprep® Bowel Prep Kit in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for the launch of a generic pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, indicating it is a regulatory announcement. The content focuses on product launch and regulatory approval, not on financial results, management changes, or detailed financial data. The document length is 4292 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, no voting results, no management discussion, or other report types. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and disclosure under listing obligations.
2022-09-09 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a licensing and supply agreement between Lupin and DKSH for marketing biosimilar candidates in the Philippines. It contains no financial statements, regulatory filings, or detailed financial data. It is a corporate announcement about a business partnership and product commercialization, not a financial report, regulatory filing, or management report. The document length is 6861 characters, which is consistent with a press release. There is no indication of an annual report, earnings release, or other formal filing. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2022-09-07 English
Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines.
Regulatory Filings Classification · 95% confidence The document is a press release announcing a licensing and supply agreement between Lupin Limited and DKSH for biosimilar commercialization in the Philippines. It is dated September 7, 2022, and is addressed to stock exchanges and regulatory bodies as a disclosure pursuant to SEBI Listing Regulations. The content focuses on the business partnership and product pipeline, with no financial statements, earnings data, or detailed financial analysis. The document is approximately 7,546 characters, which is relatively short and primarily an announcement rather than a detailed report. It does not contain quarterly or annual financial results, management discussion, or audit information. Therefore, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and disclosure of a material business development that does not fit into other specific categories like earnings release, annual report, or capital update.
2022-09-07 English
Lupin Receives Tentative Approval from U.S. FDA for Dasatinib Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Dasatinib Tablets. It is addressed to stock exchanges and references Regulation 30 of SEBI Listing Regulations, which pertains to disclosure of material events. The content is a corporate announcement about regulatory approval and does not contain financial statements, management discussion, or detailed financial data. The document length is 4720 characters, which is relatively short and typical for a press release. It is not an annual report, earnings release, or any detailed financial or governance report. It is a regulatory disclosure announcement about a material event (FDA approval). Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-08-29 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Dasatinib Tablets. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, 2015. The content is an announcement of a regulatory approval event and does not contain financial statements, management discussion, or detailed financial data. It is not a full report, earnings release, or management commentary. The document is a regulatory announcement about a significant corporate event (FDA approval) relevant to investors and the market. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-08-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.